Merlintrader
Nov 14, 11:08 PM
$BCTX Nov 6: BriaCell and BriaPro presented preclinical findings across four SITC posters, including Bria-OTS+ immune activation and BP-80 tolerability in primates. These are preclinical findings and do not establish efficacy in patients.
Not investment advice.
More context and primary sources in our
$BCTX stock hub:
https://www.merlintrader.com/briacell-therapeutics-stock-hub/
0 replies